Janux Therapeutics, Inc.
JANX
$13.99
-$0.06-0.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -64.69% | -68.32% | -139.85% | -39.84% | -18.36% |
| Total Depreciation and Amortization | -1.50% | -0.29% | 0.63% | 0.64% | 5.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.94% | -7.21% | 144.24% | 102.90% | 82.15% |
| Change in Net Operating Assets | 880.15% | 14,378.79% | 198.39% | 144.81% | 110.45% |
| Cash from Operations | -87.69% | -90.37% | -28.68% | 10.68% | 13.37% |
| Capital Expenditure | -190.53% | -17.67% | 28.66% | 69.75% | 80.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -16.41% | -5.58% | 17.63% | -235.21% | -554.90% |
| Cash from Investing | -16.65% | -5.62% | 17.67% | -231.54% | -526.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.26% | 18.81% | 2.03% | 3.11% | 1,097.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.31% | 18.70% | 1.94% | 3.02% | 1,097.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -191.95% | 125.32% | 298.43% | -176.22% | 1,376.81% |